Summary The growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian malignancy, benign ovarian tumours and non-tumour related gynaecological conditions have been investigated using an ovarian carcinoma cell line (OAW 42) (La Rocca & Rheinwald, 1985) .
Following reports that cell-free ascites from cancer patients could stimulate tumour cell growth in vitro (Uitendaal et al., 1983) . there has been considerable interest in the growth promoting properties of these fluids (Broxterman et al., 1987; Arteaga et al., 1988; Hanauske et al., 1988; Mills et al., 1988) . In an early study we found that a mesothelial cell line and an ovarian tumour cell line showed different responses to the same fluid. Whereas tumour cells were stimulated by fluids from patients with benign and malignant tumours as well as non-tumour conditions, mesothelial cells were stimulated more specifically by the tumour-related fluids. It therefore appeared that the response of mesothelial cells could be an indicator of the presence of undefined tumour marker(s). The present study was carried out to investigate this possibility using a variety of fluids. These included cyst fluids, ascitic fluids and peritoneal fluids from patients with cancer of the ovary, benign ovarian tumours and gynaecological conditions which were not tumour related. The role of coagulation factors and EGF ± TGF-P in the growth promoting effects observed was also investigated particularly with respect to EGF, to which mesothelial cells are known to be sensitive (La Rocca & Rheinwald, 1985) .
Materials and methods

Patient groups
Ascitic fluids were collected from ovarian cancer patients (n = 42), non-ovarian cancer patients (n = 13), non-tumour patients (n = 4) and one patient with a benign ovarian tumour. Peritoneal fluids were collected from gynaecology patients undergoing laporotomy or laporoscopy for nontumour related conditions (n = 15), second-look laporotomies in ovarian cancer patients (n = 5), patients with benign ovarian tumours (n = 8) and with malignant ovarian tumours (n = 10). Cyst fluids were collected from borderline tumours (n = 3), benign tumours (n = 23) and malignant tumours (n = 11). All fluids were collected without heparin, centrifuged at 3,000 r.p.m. for 15 min to remove cells, aliquotted and frozen at -20°C.
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Target cells Growth promoting activity of the fluids was assayed against three target cell populations. These included a mesothelial cell population, 58MC, from the ascites of a patient with ovarian cancer and characterised according to criteria described elsewhere (Wilson, 1989) , the normal rat kidney fibroblast cell line, NRK-49F, and one established ovarian tumour cell line, OAW 42 (Wilson, 1984) . OAW 42 was maintained as a monolayer culture on growth medium consisting of Dulbecco's Modification of Eagle's medium supplemented with 10% fetal calf serum, 1 mM glutamine, 1 mM sodium pyruvate, 20 IU 1' insulin, penicillin and streptomycin (GM). 58MC was also grown as a monolayer on GM additionally supplemented with 5 ng ml' epidermal growth factor (EGF) (Gibco) and 0.4 ,Ag ml-' hydrocortisone (Sigma) (GM + EGF/HC). NRK-49F was maintained as a monolayer on GM without added pyruvate and insulin. All lines were subcultured at weekly intervals and stocks were confirmed to be free of mycoplasma contamination.
Soft agar assay
The growth promoting activity of the fluids was determined under anchorage-independent conditions. One ml base layers of 0.5% agar in GM were prepared in 35 (Figure 1) (Wilson, 1987 (Table I) . Na+, K+ and total protein contents were similar in the ascitic fluid, cyst fluid and peritoneal fluid groups. Glucose content was significantly lower in the cyst fluid group, as was P042-content. LH and FSH levels were determined in 65 fluids using a RIA kit (Chelsea Hospital for Women). Results are included only for LH because FSH levels exceeded the range of the assay. The levels of urogastrone (URO-EGF) and TGF-a were determined in 32 unfractionated fluids using methods which have been described elsewhere (Gregory et al., 1988 (Gregory et al., , 1989 . Briefly, biosynthetic URO-EGF and TGF-a were derived from synthetic genes expressed in E. coli and purified to give the human sequence 53 and 50 amino acid residues (Frankling et al., 1986; Gregory et al., 1988) . RIA assays for URO-EGF and TGF-a were performed using antibodies raised in rabbit and sheep respectively. The standard curves covered the range 20 pg to 1O ng for URO-EGF and 1O pg to S ng for TGF-a. Crossreactivity between URO-EGF and TGF-a was 10 1tg = 40 pg for both assays. TGF-p-like activity was determined using a mink lung epithelial cell assay, which shows a dose related inhibition of tritiated thymidine incorporation in response to TGF-P like activity (Holley et al., 1983 EGF, 0.1, 1, 10 and 25ngmlh'; TGF-P, 1, 10, 100 and 1,000pgml-'; and combinations of each concentration of EGF with all concentrations of TGF-P. Replicates of three were used for all test conditions except controls, for which 18 replicates were routinely used. Plates were scored for colonies as described previously.
Effects of thrombin and heparin on CSA and TA offluids Thrombin (Diagnostic Reagents Ltd) at 0.1 and 0.3 U ml' was added to 14 fluids. After 3 h incubation at 37°C any clots which had formed were removed and the fluids were then used in the microplate assay described above, using 58MC and OAW 42 as target cells. Fluids were added as a 1501l liquid overlay to give a final dilution of 50%. Controls consisted of untreated fluids, GM or GM + EGF/HC with and without added thrombin at 0.1 and 0.3 U ml-'. Preservative-free heparin (Monoprin) was also added to fluids at 1O U ml-' and to control media at the same concentrations, and these were included in the same experiments.
Results
Response of target cells to growth factors
The responses of each of the cell lines are shown in Figure   2a ,c,e for EGF and TGF-P added separately and in Figure  2b ,d,f for combinations of EGF and TGF-P. Briefly, 58MC and OAW 42 showed an -4-fold and -2-fold increase in plating efficiency to 25 ng ml-' of EGF, and NRK-49F also formed colonies (plating efficiency -2.2%) at this concentration of EGF. Clonogenic growth of 58MC was significantly enhanced by 1, 10 and 100 pg ml-I of TGF-P, whereas OAW 42 was significantly inhibited, (-50%) and only at 1,000 pg ml1'. With the combinations, the response of NRK-49F to EGF was significantly enhanced by TGF-P, as expected (Anzano et al., 1982) , and TGF-P also enhanced the response of 58MC to 0.1 and 1 ng ml-' of EGF, and of OAW 42 to 1 and 25 ng ml-' of EGF. Transforming activity offluids for mesothelial cells A total of 135 fluids have been tested at 50% dilution for transforming activity (TA) in a soft agar assay against one mesothelial cell population (58MC). Results are shown in Table II for the different patient groups which were investigated.
Mean TA values in the different tumour ascites groups were significantly higher than the mean TA value for the control GM group, but the mean TA of the non-tumour group (liver cirrhosis) was not significantly different from the control, indicating that higher levels of TA are tumourassociated. There were no significant differences between TA values in the different ascites sub-groups. In all the peritoneal fluid groups, mean TA values were not significantly different from the control value, although within each sub-group there was a small percentage of fluids that did have higher TA values. Most notable was a peritoneal fluid sample (volume 1.5 ml) from a 2LL-patient with residual disease (TA = 1.32). In the cyst fluid group the difference between benign and malignant cyst fluids reached borderline significance (storage times for the two groups were not significantly different, see Materials and methods), with some benign cyst fluids having high TA values and some malignant cyst fluids having low TA values. Two borderline cysts also showed higher TA values. Because of the difference between benign and malig- 
TGF-P
Fifty-six fluids have been assayed for TGF-a-like inhibitory activity using mink lung epithelial cells (MLEC) as targets.
The different values obtained in the MLEC assay are shown in Figure 5 for the various groups of fluids. 3H-Tdr values ranged from -30% to -170% indicating the presence of TGF-p-like activity in some fluids, and also EGF/TGF-z-like activity. The largest difference was observed between two groups of five benign and five malignant cysts fluids, but this difference was not significant (t = 1.599; 2P 0.2). In the untreated ovarian cancer group there were more samples showing 3H-Tdr values of > 100% (13/20). 3H-Tdr values and TA values were compared for 46 fluids giving a correlation coefficient of 0.247 which was of borderline significance (2P 00.1).
Correlation between age ofpatient, histology, staging and TA of cyst fluid and peritonealfluid Age, histology and stage The age of the patient and TA of the cyst fluid were compared for 24 patients. There was significant correlation between age of patient and TA in the pooled benign (14), borderline (3) and malignant (7) groups (r = 0.529, 2P 0.01). In the benign group only, TA and age were still significantly correlated (r = 0.742, 2P 0.01) but the correlation between age and TA was not significant in the malignant plus borderline group. In the benign group 9/14 tumours were serious or mucinous cystadenomas and six of these showed TA values ) 0.3. The remaining five tumours were either of questionable origin (3), one was a thecoma and one was a corpus luteal cyst. None of these showed values > 0.3. Elevated TA, therefore, appeared to be associated with cystadenomas, and the correlation between age and TA reflected the decreased incidence of these tumours in the younger age group. Analysis of LH levels in nine fluids from the cystadenoma group confirmed the age association, and LH levels showed a correlation with TA which was of borderline significance (r = 0.64 2P < 0. (Fox, 1990; Anderson, 1990 The nature of the putative growth factors remains unclear. Although the magnitude of the response obtained with some of the fluids were comparable to those obtained with 0.1-10 ngml-l of EGF, neither TGF-c nor EGF was detected by RIA except in two malignant cyst fluids, which contrasts with other studies, in which high levels of TGF-a were found in ascitic fluids Hanauske et al., 1988) . Reasons for the discrepancy are unclear, although it may relate to differences between the antibodies used. Evidence for the presence of TGF-P in some fluids is stronger, and is indicated both by the results with NRK-49F cells and MLEC. The concentrations predicted by these bioassays were generally in the region of 10-I00 pg ml-' and these concentrations of TGF-P alone enhanced the growth of 58MC. In the presence of EGF, these concentrations of TGF-P also enhanced the growth of OAW 42 and of 58MC beyond that obtained in the presence of either TGF-P alone or EGF alone. Levels of at least 1,000 pg ml-' of TGF-P appeared necessary for inhibition of clonogenic growth of OAW 42.
The function of TGF-P is of interest, since Mullerian inhibiting substance (MIS), which is structurally related to TGF-P, has been reported to inhibit ovarian tumour cell growth in a nude mouse model (Donahoe et al., 1981) , although in a more recent study recombinant MIS was inhibitory against only a small percentage of the tumours tested (Wallen et al., 1989) .
Mesothelial cells are capable of responding to a wide range of growth factors in monolayer (Gabrielson et al., 1988; Laveck et al., 1988) and it is quite likely that the growth factor content of the fluids is pleomorphic. Whilst TGF-.a may be implicated, other results exclude not only TGF-o, but also indicate that the growth factor is specific to ovarian cancer (Mills et al., 1988) . In this study the factors responsible for CSA and TA are not necessarily identical since elevated TA is tumour-associated whereas CSA is not and there is some indication that coagulation factors may be involved in CSA. Enhanced tumour growth in soft agar may be due to fibrin/fibrinogen polymerisation thus providing a matrix for tumour cell growth. Interestingly heparin had no effect on TA, apart from abolishing spreading, implying different target cell sensitivities to heparin. In most studies fluids have been collected with 1OUml-' of heparin and although Broxterman et al. (1987) reported that heparin had no effect on their target cells, it would appear that this is variable, and we would therefore recommend that heparin should be used with caution when analysing growth promoting activity of fluids. Other information which implicates coagulation factors as perhaps worthy of further study in ovarian cancer includes the abnormally high levels of fibrin degradation products (FDPs) and plasminogen activator in ascitic fluids (Svanberg & Astedt, 1975) ; the effects which have been achieved using anticoagulant therapy with warfarin in cancer treatment (McCulloch & George, 1989; Zacharski et al., 1984) ; the use of fibronolytic agents (tranexamic acid) to treat ascites (Astedt et al., 1977; Kikuchi et al., 1986) and the role of thrombin as a mitogenic hormone (Bar-Shavit et al., 1986; Medrano et al., 1987) .
By using different target cell lines to determine growth 0 _a__ 0 promoting activity in ascitic fluids, cysts fluids and peritoneal fluids we have shown, using tumour cells, that there is a non-specific activity (CSA), and that there is a tumourassociated activity (TA) which is only apparent using mesothelial cells as targets. Further studies on the differences between benign and malignant cysts fluids, the relationship of TA with menopausal status in benign cysts and with stage in malignant cysts may reveal a useful biological marker for improving our understanding of the aetiology of ovarian cancer.
